Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany – A national case collection

Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage

(2016) Jennifer A. Frontera et al.   CRITICAL CARE MEDICINE

Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary

(2016) Hein Heidbuchel et al.   EUROPEAN HEART JOURNAL

Systemic Thrombolysis for Ischemic Stroke after Antagonizing Dabigatran with Idarucizumab—A Case Report

(2016) Niklas Schäfer et al.   Journal of Stroke & Cerebrovascular Diseases

Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke

(2016) Joachim G. Schulz et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Letter by Tsuda Regarding Article, “Obstructive Sleep Apnea in Acute Stroke: A Role for Systemic Inflammation”

(2016) Kazushi Tsuda   STROKE

Intravenous Thrombolysis With Recombinant Tissue-Type Plasminogen Activator in a Stroke Patient Receiving Dabigatran Anticoagulant After Antagonization With Idarucizumab: Table.

(2016) Jörg Berrouschot et al.   STROKE

Systemic Thrombolysis for Ischemic Stroke after Antagonizing Dabigatran with Idarucizumab—A Case Report

(2016) Niklas Schäfer et al.   Journal of Stroke & Cerebrovascular Diseases

Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants

(2016) Jan C. Purrucker et al.   JAMA Neurology

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

(2015) Hein Heidbuchel et al.   EUROPACE

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial

(2015) Stephan Glund et al.   LANCET

Idarucizumab for Dabigatran Reversal

(2015) Charles V. Pollack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Additional Events in the RE-LY Trial

(2014) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

(2013) Christian T Ruff et al.   LANCET

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran

(2012) Robert G. Hart et al.   STROKE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial

(2010) Hans-Christoph Diener et al.   LANCET NEUROLOGY

Newly Identified Events in the RE-LY Trial

(2010) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE